Regenerative Medical Solutions

Regenerative Medical Solutions (RMS) is a clinical-stage biotech company pioneering an iPSC-derived islet cell therapy as a potential functional cure for diabetes. Founded in 2012 based on decades of academic research from Dr. Jon Odorico's lab at the University of Wisconsin, the company is developing a scalable cell product designed to avoid the need for heavy immunosuppression or implantable devices. RMS is actively seeking investment and strategic partnerships with pharmaceutical and biotech companies to advance its therapy through clinical trials and to the market.

Proprietary protocol for differentiating human induced pluripotent stem cells (iPSCs) into functional pancreatic beta islet cells. Platform aims to create a scalable, ethically-sourced cell therapy designed to avoid heavy immunosuppression.

RMS competes in a crowded and well-funded space for diabetes cell therapies, facing companies like Vertex Pharmaceuticals (with donor-derived islet cells in Phase 3) and other biotechs developing iPSC-derived islets. Differentiation claims center on avoiding immunosuppression and ethical sourcing, but these must be clinically proven.